Search research articles
Contact Us
Filters
Showing results (151-160 of 159) with videos related to
Page
of 16
Sort By:
You have reached the last page of results.
This site can display upto 159 results.
Chinese Medical Journal
|
January 17, 2025
Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study
Yuankai Shi, Qingyuan Zhang, Junsheng Wang, et al.
Cancer Research
|
February 24, 2025
The Glycosyltransferase XYLT1 Activates NF-κB Signaling to Promote Metastasis of Early-Stage Lung Adenocarcinoma
Jian Han, Jianan Du, Xiangmeng Li, et al.
Innovation (Cambridge (Mass.))
|
January 28, 2025
Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Luoyan Ai, Qian Li, Shilong Zhang, et al.
Cancer Immunology, Immunotherapy : CII
|
March 8, 2025
Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies
Zhihao Lu, Guoping Sun, Jiancheng Li, et al.
The Lancet. Gastroenterology & Hepatology
|
January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
Xiangrui Meng, Tao Wu, Yonggui Hong, et al.
Annals of Translational Medicine
|
January 20, 2023
Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01)
Yijie Ma, Weijie Zhao, Peichun Sun, et al.
BMC Medicine
|
May 5, 2023
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
Jin Li, Shukui Qin, Lu Wen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
Xiangrui Meng, Junsheng Wang, Jin Xia, et al.
Cancer Cell
|
March 4, 2022
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Zi-Xian Wang, Chengxu Cui, Jun Yao, et al.
Page
of 16
Search research articles
Search
Showing results (151-160 of 159) with videos related to
Sort By:
Page
of 16
You have reached the last page of results.
This site can display upto 159 results.
Chinese Medical Journal
|
January 17, 2025
Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study
Yuankai Shi, Qingyuan Zhang, Junsheng Wang, et al.
Cancer Research
|
February 24, 2025
The Glycosyltransferase XYLT1 Activates NF-κB Signaling to Promote Metastasis of Early-Stage Lung Adenocarcinoma
Jian Han, Jianan Du, Xiangmeng Li, et al.
Innovation (Cambridge (Mass.))
|
January 28, 2025
Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study
Luoyan Ai, Qian Li, Shilong Zhang, et al.
Cancer Immunology, Immunotherapy : CII
|
March 8, 2025
Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: an individual patient data pooled analysis of 987 patients from three prospective cohort studies
Zhihao Lu, Guoping Sun, Jiancheng Li, et al.
The Lancet. Gastroenterology & Hepatology
|
January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
Xiangrui Meng, Tao Wu, Yonggui Hong, et al.
Annals of Translational Medicine
|
January 20, 2023
Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01)
Yijie Ma, Weijie Zhao, Peichun Sun, et al.
BMC Medicine
|
May 5, 2023
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
Jin Li, Shukui Qin, Lu Wen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 22, 2024
Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study
Xiangrui Meng, Junsheng Wang, Jin Xia, et al.
Cancer Cell
|
March 4, 2022
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
Zi-Xian Wang, Chengxu Cui, Jun Yao, et al.
Page
of 16